leisure time -WSS

leisure time

author：hotspot 2025-09-14 14:43:14 - browse：794

An import ban of certain Apple Watches officially goes into effect on Tuesday. Justin Sullivan/Getty Images

An import ban of certain Apple Watches officially goes into effect on Tuesday, after the U.S. International Trade Commission deemed the blood oxygen measurement feature too similar to products patented by pulse oximetry company Masimo. It’s the first time Apple has ever faced such a ban.

President Biden had the chance to veto the ban until Christmas day, but he didn’t, as a statement from his trade representative made clear Tuesday morning. Now, Apple has to decide how much it values this feature, and if it’s willing to take a hit on its journey to establish the Apple Watch as a necessary public health tool.

“We strongly disagree with the USITC decision and resulting exclusion order, and are taking all measures to return Apple Watch Series 9 and Apple Watch Ultra 2 to customers in the U.S. as soon as possible,” Apple spokesperson Nikki Rothberg wrote in an email to STAT.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Independent physicians launch a new lobbying group

WSS

Celebrate National Dole Whip Day for 3 days this week at Disney

Copay coupons to count toward deductibles, after Biden court move

Elizabeth Holmes banned from government health programs

TikTok cracks down on users posting about weight loss drugs

Norman Reedus' Daryl Dixon

Independent physicians launch a new lobbying group

hotspot

leisure time

knowledge

Heart attack and stroke risk calculators need revising

Copay coupons to count toward deductibles, after Biden court move

Moonlake's readout produced a cash windfall. Risks remain

New brain studies show LSD's effects on the brain in full color

After affirmative action ruling, medical educators look to 'holistic review'

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

DIEP, the 'gold standard' of breast reconstruction, is under threat

States increasingly look to regulate hospital facility fees

Medicare details structure of new drug price negotiation program

No Labels group has 'steep climb,' but third party 'worth trying': Larry Hogan

leisure time

eGenesis tests gene

Resistance to cancer drugs: A new genetic explanation

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

EU regulator recommends expanding Mounjaro approval to obesity

STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

hotspot

leisure time

Wikipedia

explore